 |
 |
| August 2009 |
|
Rose presents data on inhaled delivery of ROSE-010 at Neurogastroenterology and Motility meeting Chicago, August 2009.
|
| ROSE-010 has been efficiently delivered by inhaled delivery through the lung with comparable bioavailability and pharmacology when compared to subcutaneous or intravenous delivery. The study was carried out by Prof Per Hellström (Karolinska, Sweden) in an established model of intestinal motility and using MannKind Corporation’s Technosphere particulate delivery system (www.mammkindcorp.com). This new development shows the potential for IBS treatment by an inhaled formulation of ROSE-010. |
| To view the abstract please click here |
|
| August 2009 |
|
Rose presents data on mechanism of action of ROSE-010 at Neurogastroenterology and Motility meeting, Chicago, August 2009.
|
| ROSE-010, a GLP-1 analogue, exerts its effect on small intestine motility and contractility through the GLP-1 receptor. Blockage of the receptor eliminates the ROSE-010 response. These results show that the mechanism of action of ROSE-010 is mediated through the GLP-1 receptor and suggest that ROSE-010 is exploiting a natural feedback mechanism in digestion in the treatment of IBS. |
| To view the abstract please click here |
|
| January 2009 |
| Results of positive Phase IIa clinical results for ROSE-010 in treatment of IBS published, January 2009. |
|
This randomized, placebo-controlled, double-blind study in 166 IBS patients showed that ROSE-010 was well tolerated and provided fast and effective relief of acute pain attacks on demand. A greater percentage of patients were very satisfied with ROSE-010 compared to placebo and rated ROSE-010 significantly better than previously prescribed IBS medications.
|
| For a copy of the publication (Hellström et al., Aliment Pharmacol Ther 29, 198-206) please click here |
|
| November 2008 |
| Gastrotech signs licensing agreement with Eli Lilly and Company for compound to treat Irritable Bowel Syndrome |
| Gastrotech Pharma, a biopharmaceutical R&D company with a focus on the medical applications of gastrointestinal hormones, has signed an agreement with Eli Lilly and Company. |
| Read more |
|
|
